Daraxonrasib improves overall survival to 13.2 months in mPDAC patients compared to 6.7 months
Trial shows daraxonrasib improves survival for pancreatic cancer patients
This Phase 3 randomized trial of 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma found daraxonrasib signifi…
A Phase 3 trial found that daraxonrasib significantly extended survival times for patients with specific types of metastatic pancreatic canc…
SCOPE platform predicts outcomes for metastatic colorectal and pancreatic cancers using organoid screening
A Lab-Built Tumor Test May Predict If Cancer Drugs Will Work
This preclinical platform development study utilized a machine learning system integrating patient-derived organoids and clinical data to pr…
A platform called SCOPE uses tiny lab-grown copies of a patient's tumor to predict — before a large trial even starts — whether a cancer dru…